Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Magnesium silicate
- DrugBank Accession Number
- DB13249
- Background
Magnesium silicate is a compound of magnesium oxide and silicon. It is the magnesium salt of silicic acid containing an unspecified amount of water. The molecular formula can be expressed more clearly as MgSiO3.xH2O.1 It is known as talc and it presents many uses in the cosmetic industry, food industry and pharmaceutical industry.2 Under the FDA, magnesium silicate is determined as a member of the substances generally recognized as safe (GRAS) to be used as an anticaking agent.3
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Magnesium silicate (DB13249)
- Weight
- Average: 100.387
Monoisotopic: 99.9467121 - Chemical Formula
- MgO3Si
- Synonyms
- Not Available
Pharmacology
- Indication
Magnesium silicate is used to absorb moisture, prevent caking, and to improve the feel of a product. In the pharmaceutical companies, it is used as a dietary supplement, as part of the formulation ingredients in drug production, in antacid and antiulcer preparations, as a component of antiepileptic drugs, in antifungal topical agents and in the treatment of acne and as a facial moisturizer.2
When complexed with arginine, magnesium silicate can be used as an antiatherosclerotic agent and to promote bone and cartilage formation in mammals.1
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
As a supplement, magnesium silicate acts by replacing the factor that is missing. In the case of antacids, it is a non-absorbable antacid whose main activity is related to the absorption of hydrochloric acid. More specifically, magnesium silicate acts as a neutralizing and astringent agent.5
- Absorption
Orally administered magnesium silicate is rapidly neutralized in the stomach and it forms magnesium chloride and silicon dioxide. From the modified portion, some of the formed magnesium is absorbed.1 The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5
- Volume of distribution
The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5
- Protein binding
The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5
- Metabolism
The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5
- Route of elimination
The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5
- Half-life
The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5
- Clearance
The very low absorption of magnesium silicate makes its pharmacokinetic properties not relevant.5
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The administration of more than 50 meq of magnesium daily can produce the development of hypermagnesemia. This can provoke the formation of bladder and renal calculi. There is no known toxicity and the LD50 in animals are higher than 500 mg/kg in humans.1 It is determined that magnesium silicate is not carcinogenic.4
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetaminophen Magnesium silicate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. Acetophenazine Magnesium silicate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium silicate. Alfacalcidol The serum concentration of Magnesium silicate can be increased when it is combined with Alfacalcidol. Alimemazine Magnesium silicate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Formula EC Magnesium silicate (12.5 mg / tab) + Calcium carbonate (250 mg / tab) + Cupric sulfate (0.5 mg / tab) + Ergocalciferol (100 unit / tab) + Magnesium oxide (125 mg / tab) + Manganese sulfate (2.5 mg / tab) + Pyridoxine hydrochloride (2.5 mg / tab) + Zinc sulfate (3.75 mg / tab) Tablet Oral Body Wise International Llc Not applicable Not applicable Canada 
Categories
- ATC Codes
- A02AA05 — Magnesium silicate
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkaline earth metal oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is an alkaline earth metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkaline earth metal organides
- Sub Class
- Alkaline earth metal oxides
- Direct Parent
- Alkaline earth metal oxides
- Alternative Parents
- Metalloid salts / Inorganic salts / Inorganic oxides
- Substituents
- Alkaline earth metal oxide / Inorganic metalloid salt / Inorganic oxide / Inorganic salt
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 9B9691B2N9
- CAS number
- 1343-88-0
- InChI Key
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N
- InChI
- InChI=1S/Mg.3O.Si/q+2;3*-2;+4
- IUPAC Name
- silicon(4+) ion magnesium(2+) ion trioxidandiide
- SMILES
- [O--].[O--].[O--].[Mg++].[Si+4]
References
- General References
- Rashid I., Nidal H. Daraghmeh M., Omari A., Babur Z., Chowdhry S., Leharne H., Adnan A. (2011). Profiles of drug substances and related methodology. Academic Press. [ISBN:978-0-12-387667-6]
- FDA Ingredients [Link]
- FDA code of federal regulations [Link]
- Toxnet [Link]
- Lecture [File]
- External Links
- MSDS
- Download (47.4 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Recruiting Treatment Burning Mouth Syndrome 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 1910 ºC 'MSDS' water solubility Insoluble Monograph - Predicted Properties
Property Value Source logP -0.65 Chemaxon pKa (Strongest Acidic) 15.7 Chemaxon pKa (Strongest Basic) -1.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 13.11 m3·mol-1 Chemaxon Polarizability 0.95 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at June 23, 2017 20:38 / Updated at January 09, 2021 18:41